KRRO Stock Overview
A biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Select a narrative for quick price alerts from the community, or create your own.
Korro Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$18.09 |
| 52 Week High | US$98.00 |
| 52 Week Low | US$11.13 |
| Beta | 0 |
| 1 Month Change | 3.73% |
| 3 Month Change | -51.00% |
| 1 Year Change | -71.25% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 16.86% |
Recent News & Updates
Recent updates
Shareholder Returns
| KRRO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 30.1% | 3.6% | 4.8% |
| 1Y | -71.3% | -4.1% | 7.8% |
Return vs Industry: KRRO underperformed the US Biotechs industry which returned -3.2% over the past year.
Return vs Market: KRRO underperformed the US Market which returned 7.7% over the past year.
Price Volatility
| KRRO volatility | |
|---|---|
| KRRO Average Weekly Movement | 14.5% |
| Biotechs Industry Average Movement | 11.5% |
| Market Average Movement | 7.8% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: KRRO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: KRRO's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 104 | Ram Aiyar | www.korrobio.com |
Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. Its lead product candidate is KRRO-110 which is in Phase 1/2 clinical trial for the treatment of Alpha-1 Antitrypsin Deficiency (AATD). It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates.
Korro Bio, Inc. Fundamentals Summary
| KRRO fundamental statistics | |
|---|---|
| Market cap | US$169.85m |
| Earnings (TTM) | -US$83.58m |
| Revenue (TTM) | US$2.27m |
74.8x
P/S Ratio-2.0x
P/E RatioIs KRRO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| KRRO income statement (TTM) | |
|---|---|
| Revenue | US$2.27m |
| Cost of Revenue | US$0 |
| Gross Profit | US$2.27m |
| Other Expenses | US$85.85m |
| Earnings | -US$83.58m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -8.90 |
| Gross Margin | 100.00% |
| Net Profit Margin | -3,680.36% |
| Debt/Equity Ratio | 0% |
How did KRRO perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/04/27 10:06 |
| End of Day Share Price | 2025/04/25 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Korro Bio, Inc. is covered by 11 analysts. 9 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Konstantinos Biliouris | BMO Capital Markets Equity Research |
| Tu Cam Nguyen | CGS International |
| Keay Nakae | Chardan Capital Markets, LLC |